Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 263

1.

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.

El Ghorayeb N, Rondeau G, Latour M, Cohade C, Olney H, Lacroix A, Perrotte P, Sabourin A, Mazzuco TL, Bourdeau I.

Medicine (Baltimore). 2016 Mar;95(13):e3180. doi: 10.1097/MD.0000000000003180.

2.

Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes.

Trudeau V, Gandaglia G, Shiffmann J, Popa I, Shariat SF, Montorsi F, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

Can Urol Assoc J. 2014 Sep;8(9-10):E695-701. doi: 10.5489/cuaj.2051.

3.

Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study.

Larouche A, Becker A, Schiffmann J, Roghmann F, Gandaglia G, Hanna N, Tian Z, Perrotte P, Schlomm T, Graefen M, Ahyai S, Trinh QD, Karakiewicz PI, Sun M.

Can Urol Assoc J. 2014 May;8(5-6):E419-24. doi: 10.5489/cuaj.1790.

4.

The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.

Gandaglia G, Karakiewicz PI, Abdollah F, Becker A, Roghmann F, Sammon JD, Kim SP, Perrotte P, Briganti A, Montorsi F, Trinh QD, Sun M.

Eur J Surg Oncol. 2014 Dec;40(12):1706-15. doi: 10.1016/j.ejso.2014.05.001. Epub 2014 May 22.

PMID:
24915856
5.

Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Sun M, Trinh QD, Perrotte P, Karakiewicz PI.

Eur Urol. 2014 May;65(5):1014-5. doi: 10.1016/j.eururo.2013.12.042. No abstract available.

PMID:
24646500
6.

Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy.

Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, Meskawi M, Trinh QD, Shariat SF, Perrotte P, Chun FK, Graefen M, Karakiewicz PI.

Can Urol Assoc J. 2014 Jan-Feb;8(1-2):E75-80. doi: 10.5489/cuaj.749.

7.

Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample.

Becker A, Bianchi M, Hansen J, Tian Z, Shariat SF, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

World J Urol. 2014 Dec;32(6):1511-21. doi: 10.1007/s00345-014-1256-y. Epub 2014 Feb 11.

PMID:
24515596
8.

Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments.

Gandaglia G, Abdollah F, Hu J, Kim S, Briganti A, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI, Trinh QD, Sun M.

J Endourol. 2014 Jul;28(7):784-91. doi: 10.1089/end.2013.0774. Epub 2014 Mar 24.

PMID:
24499306
9.

Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.

Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, Hu JC, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Abdollah F.

BJU Int. 2014 Dec;114(6b):E62-E69. doi: 10.1111/bju.12645. Epub 2014 Jul 15.

10.

The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period.

Gandaglia G, Trinh QD, Hu JC, Schiffmann J, Becker A, Roghmann F, Popa I, Tian Z, Perrotte P, Montorsi F, Briganti A, Karakiewicz PI, Sun M, Abdollah F.

Eur J Surg Oncol. 2014 Sep;40(9):1080-6. doi: 10.1016/j.ejso.2013.12.016. Epub 2014 Jan 2.

PMID:
24411705
11.

A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.

Ismail S, Meskawi M, Hansen J, Bianchi M, Tian Z, Latour M, Graefen M, Montorsi F, Trinh QD, Perrotte P, Karakiewicz PI, Sun M.

Crit Rev Oncol Hematol. 2014 Apr;90(1):49-57. doi: 10.1016/j.critrevonc.2013.12.003. Epub 2013 Dec 12. Review.

PMID:
24411587
12.

Local tumor destruction in renal cell carcinoma--an inpatient population-based study.

Trudeau V, Becker A, Roghmann F, Shariat SF, Kluth LA, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

Urol Oncol. 2014 Jan;32(1):54.e1-7. doi: 10.1016/j.urolonc.2013.08.030.

PMID:
24360664
13.

Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M.

Prostate. 2014 Feb;74(2):210-6. doi: 10.1002/pros.22742. Epub 2013 Oct 16.

PMID:
24132735
14.

Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis.

Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

BJU Int. 2014 May;113(5):733-40. doi: 10.1111/bju.12288. Epub 2013 Sep 5.

15.

Robot-assisted vs. laparoscopic partial nephrectomy: utilization rates and perioperative outcomes.

Sammon JD, Karakiewicz PI, Sun M, Ravi P, Ghani KR, Jeong W, Bianchi M, Hansen J, Perrotte P, Peabody JO, Rogers CG, Shariat SF, Menon M, Trinh QD.

Int Braz J Urol. 2013 May-Jun;39(3):377-86. doi: 10.1590/S1677-5538.IBJU.2013.03.11.

16.

Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma.

Meskawi M, Becker A, Bianchi M, Trinh QD, Roghmann F, Tian Z, Graefen M, Perrotte P, Karakiewicz PI, Sun M.

Int J Urol. 2014 Feb;21(2):122-8. doi: 10.1111/iju.12204. Epub 2013 Jul 2.

17.

In-hospital mortality and failure-to-rescue rates after radical cystectomy.

Trinh VQ, Trinh QD, Tian Z, Hu JC, Shariat SF, Perrotte P, Karakiewicz PI, Sun M.

BJU Int. 2013 Jul;112(2):E20-7. doi: 10.1111/bju.12214.

18.

Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.

Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):E283-9. doi: 10.1111/bju.12115.

19.

Sociodemographic disparities in the treatment of small renal masses.

Becker A, Roghmann F, Trinh QD, Hansen J, Tian Z, Shariat SF, Noldus J, Perrotte P, Graefen M, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):E274-82. doi: 10.1111/bju.12111.

20.

An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis.

Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):1184-90. doi: 10.1111/bju.12084. Epub 2013 Apr 12.

Supplemental Content

Loading ...
Support Center